Patents by Inventor Mikako KAWASHIMA

Mikako KAWASHIMA has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Urea derivative or pharmacologically acceptable salt thereof
    Patent number: 10858314
    Abstract: The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the urea compound or the pharmacologically acceptable salt thereof and a pharmaceutical use thereof. It has been found that a urea derivative represented by the general formula (I) below or a pharmacologically acceptable salt thereof has a superior FPRL1 agonist effect. Compound (I) or a pharmacologically acceptable salt thereof is highly useful for treatment, prevention, or suppression of inflammatory diseases, chronic airway diseases, cancers, septicemia, allergic symptoms, HIV retrovirus infection, circulatory disorders, neuroinflammation, nervous disorders, pains, prion diseases, amyloidosis, immune disorders and the like.
    Type: Grant
    Filed: May 26, 2016
    Date of Patent: December 8, 2020
    Assignee: Kyorin Pharmaceutical Co., Ltd.
    Inventors: Hiroyasu Takahashi, Hiroyuki Watanabe, Kiyoshi Fujii, Mitsuhito Shibasaki, Mikako Kawashima, Megumi Kamiya, Kohei Ohata
  • UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF
    Publication number: 20180208552
    Abstract: The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the urea compound or the pharmacologically acceptable salt thereof, and a pharmaceutical use thereof. It has been found that a urea derivative represented by the general formula (I) below or a pharmacologically acceptable salt thereof has a superior FPRL1 agonist effect. Compound (I) or a pharmacologically acceptable salt thereof is highly useful for treatment, prevention, or suppression of inflammatory diseases, chronic airway diseases, cancers, septicemia, allergic symptoms, HIV retrovirus infection, circulatory disorders, neuroinflammation, nervous disorders, pains, prion diseases, amyloidosis, immune disorders and the like.
    Type: Application
    Filed: May 26, 2016
    Publication date: July 26, 2018
    Applicant: KYORIN PHARMACEUTICAL CO., LTD.
    Inventors: Hiroyasu TAKAHASHI, Hiroyuki WATANABE, Kiyoshi FUJII, Mitsuhito SHIBASAKI, Mikako KAWASHIMA, Megumi KAMIYA, Kohei OHATA